Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study by Jonathan W. Riess, MD, Matthew S. Lara, BS, Miguel Lopez de Rodas, MD, Guillaume Luxardi, PhD, Samantha Herbert, MSPH, Michiko Shimoda, PhD, Karen Kelly, MD, Alexander Meerlev, PhD, Elizabeth Moore, MD, Laurel Beckett, PhD, Arta Monjazeb, MD, PhD, Kurt Schalper, MD, PhD, Emanual Maverakis, MD, David R. Gandara, MD

Get full text